Depot naltrexone: Antagonism of the reinforcing, subjective, and physiological effects of heroin

Psychopharmacology

Volumn 189, Issue 1, 2006, Pages 37-46

  Sullivan, Maria A ^a   Vosburg, Suzanne K ^a   Comer, Sandra D ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Depotrex ; Heroin; Humans; Naltrexone; Opioids; Subjective effects; Sustained release

Indexed keywords

DEPOTREX; DIAMORPHINE; DOCUSATE SODIUM; IBUPROFEN; IRON; MAGNESIUM HYDROXIDE; MULTIVITAMIN; MYLANTA; NALTREXONE; PARACETAMOL;

ADULT; ARTICLE; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DETOXIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HEROIN DEPENDENCE; HUMAN; LUNG FUNCTION; MALE; PERFORMANCE; PRIORITY JOURNAL; PUPIL; RATING SCALE; REINFORCEMENT; SAMPLING; SUSTAINED RELEASE FORMULATION; TASK PERFORMANCE; WITHDRAWAL SYNDROME;

ADULT; AFFECT; CARDIOVASCULAR SYSTEM; CHOICE BEHAVIOR; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEROIN; HEROIN DEPENDENCE; HUMANS; LIVER; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; PUPIL; SELF ADMINISTRATION; TIME FACTORS; TOKEN ECONOMY;

EID: 33750216033     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0509-x     Document Type: Article

References (37)

1. Alim TN, Tai B, Chiang CN, Green T, Rosse RB, Lindquist T, Deutsch SI (1995) Tolerability study of a depot form of naltrexone substance abusers. In: Harris LS (ed) Problems of drug dependence 1994, vol 2. NIDA Research Monograph No. 153 (NIH Publ. No. 95-3883). U.S. Government Printing Office, Washington, D.C., p 253
2. Callahan EJ, Rawson RA, McCleave B, Arias R, Glazer M, Liberman RP (1980) The treatment of heroin addiction: naltrexone alone and with behavior therapy. Int J Addict 15(6):795-807
3. Chiang CN, Hollister LE, Gillespie HK, Foltz RL (1985a) Clinical evaluation of a naltrexone sustained-release preparation. Drug Alcohol Depend 16:1-8
4. Chiang CN, Kishimoto A, Barnett G, Hollister LE (1985b) Implantable narcotic antagonists: a possible new treatment for narcotic addiction. Psychopharmacol Bull 21:672-675
5. Comer SD, Collins ED (2002) Self-administration of intravenous buprenorphine and buprenorphine/naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther 303 (2):695-703
6. Comer SD, Collins ED, Fischman MW (1997) Choice between money and intranasal heroin in morphine-maintained humans. Behav Pharmacol 8:667-690
7. Comer SD, Collins ED, Wilson ST, Donovan MR, Foltin RW, Fischman MW (1998) Effect of an alternative reinforcer on i.v. heroin self-administration by humans. Eur J Pharmacol 345:13-26
8. Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW (2002) Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology 159:351-360
9. Comer SD, Walker EA, Collins ED (2005) Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology 181(4):664-675
10. Crowley TJ, Wagner JE, Zerbe G, Macdonald M (1985) Naltrexone-induced dysphoria in former opioid addicts. Am J Psychiatry 142:1081-1084
11. Evans SM, Foltin RW, Levin FR, Fischman MW (1995) Behavioral and subjective effects of DN-2327 (pazinaclone) and alprazolam in normal volunteers. Behav Pharmacol 6:176-186
12. Foltin RW, Fischman MW (1992) The cardiovascular and subjective effects of intravenous cocaine and morphine combinations in humans. J Pharmacol Exp Ther 261:623-632
13. Foltin RW, Fischman MW (1995) Interaction of buprenorphine with cocaine-morphine combinations. Exp Clin Psychopharmacol 3 (3):261-269
14. Fraser HF, Van Horn GD, Martin WR, Wolbach AB, Isbell H (1961) Methods for evaluating addiction liability. (A) "Attitude" of opiate addicts toward opiate-like drugs, (B) A short-term "direct" addiction test. J Pharmacol Exp Ther 133:371-387
15. Gossop M, Green L, Phillips G, Bradley B (1989) Lapse, relapse, and survival among opiate addicts after treatment: a prospective follow-up study. Br J Psychiatry 154:348-353
16. Greenstein RA, Arndt IC, McLellan AT, O'Brien CP, Evans B (1984) Naltrexone: a clinical perspective. J Clin Psychiatry 45:25-28
17. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD (1987) Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 13:293-308
18. Heishman SJ, Francis-Wood A, Keenan RM, Chiang CN, Terrill JB, Tai B, Henningfield JE (1994) Safety and pharmacokinetics of a new formulation of naltrexone. In: Harris LS (ed) Problems of drug dependence 1993, vol 2. NIDA Research Monograph No. 141 (NIH Publ. No. 94-3749). U.S. Government Printing Office, Washington, D.C., p 82
19. Heishman SJ, Schuh KJ, Schuster CR, Henningfield JE, Goldberg SR (2000) Reinforcing and subjective effects of morphine in human opioid abusers: effect of dose and alternative reinforcer. Psychopharmacology 148:272-280
20. Hollister LE, Johnson K, Boukhabza D, Gillespie HK (1981) Aversive effects of naltrexone in subjects not dependent on opiates. Drug Alcohol Depend 8:37-41
21. Hollister LE, Schwin RL, Kapser P (1977) Naltrexone treatment of opiate-dependent persons. Drug Alcohol Depend 2:203-209
22. Judson BA, Carney TM, Goldstein A (1981) Naltrexone treatment of heroin addiction: efficacy and safety in a double-blind dosage comparison. Drug Alcohol Depend 7:325-346
23. Kelly TH, Foltin RW, Emurian CS, Fischman MW (1993) Performance-based testing for drugs of abuse: dose and time profiles of marijuana, amphetamine, alcohol, and diazepam. J Anal Toxicol 17:264-272
24. Kirchmayer U, Davoli M, Verster A, Amato L, Feri M, Perucci CA (2002) A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction 97 (10):1241-1249
25. Kosten TR, Kleber HD (1984) Strategies to improve compliance with narcotic antagonists. Am J Drug Alcohol Abuse 10:249-266
26. Kranzler HR, Modesto-Lowe V, Nuwayser ES (1998) Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res 22:1074-1079
27. Lamb RJ, Preston KL, Schindler CW, Meisch RA, Davis F, Katz JL, Henningfield JE, Goldberg SR (1991) The reinforcing and subjective effects of morphine in post-addicts: a dose-response study. J Pharmacol Exp Ther 259:1165-1173
28. Martin WR, Jasinski DR, Mansky PA (1973) Naltrexone, an antagonist for the treatment of heroin dependence. Arch Gen Psychiatry 28:784-791
29. Martin W, Sandquist VL (1974) A sustained release depot for narcotic antagonists. Arch Gen Psychiatry 30:31-33
30. McLeod DR, Griffiths RR, Bigelow GE, Yingling J (1982) An automated version of the Digit Symbol Substitution Test (DSST). Behav Res Meth Instrum 14:463-466
31. Mirin SM, Meyer RE, McNamee HB (1976) Psychopathology, craving, and mood during heroin acquisition: an experimental study. Int J Addict 11:525-544
32. Oncken C, Kirk JV, Kranzler HR (2001) Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacology 154:397-402
33. Rothenberg JL, Sullivan MA, Church SH, Seracini A, Collins E, Kleber HD, Nunes EV (2002) Behavioral naltrexone therapy: an integrated therapy for opiate dependence. J Subst Abuse Treat 23 (4):351-360
34. Sideroff SI, Charuvastra VS, Jarvik ME (1978) Craving in heroin addicts maintained on the opiate antagonist naltrexone. Am J Drug Alcohol Abuse 5:415-423
35. Wang RIH, Wiesen RL, Lamid S, Roh BL (1974) Rating the presence and severity of opiate dependence. Clin Pharmacol Ther 16:653-658
36. Washton AM, Gold MS, Pottash AC (1984) Successful use of naltrexone in addicted physicians and business executives. Adv Alcohol Subst Abuse 4(2):89-96
37. Wesnes K, Warburton DM (1983) Effects of smoking on rapid information processing performance. Neuropsychobiology 9:223-229